Unlocking the therapeutic potential of primary tumor-draining lymph nodes

Jossie Rotman; Bas D. Koster; Ekaterina S. Jordanova; A. Marijne Heeren; Tanja D. de Gruijl

doi:10.1007/s00262-019-02330-y

Unlocking the therapeutic potential of primary tumor-draining lymph nodes

Jossie Rotman, Bas D. Koster, Ekaterina S. Jordanova, A. Marijne Heeren, Tanja D. de Gruijl

Research output: Contribution to journal › Review article › Academic › peer-review

Abstract

Lymph nodes draining the primary tumor are essential for the initiation of an effective anti-tumor T-cell immune response. However, cancer-derived immune suppressive factors render the tumor-draining lymph nodes (TDLN) immune compromised, enabling tumors to invade and metastasize. Unraveling the different mechanisms underlying this immune escape will inform therapeutic intervention strategies to halt tumor spread in early clinical stages. Here, we review our findings from translational studies in melanoma, breast, and cervical cancer and discuss clinical opportunities for local immune modulation of TDLN in each of these indications.

Original language	English
Pages (from-to)	1681-1688
Number of pages	8
Journal	Cancer Immunology, Immunotherapy
Volume	68
Issue number	10
DOIs	https://doi.org/10.1007/s00262-019-02330-y
Publication status	Published - 1 Oct 2019

Access to Document

10.1007/s00262-019-02330-y

Cite this

@article{a9a75e519b644e2cbb4863e47b35d686,

title = "Unlocking the therapeutic potential of primary tumor-draining lymph nodes",

abstract = "Lymph nodes draining the primary tumor are essential for the initiation of an effective anti-tumor T-cell immune response. However, cancer-derived immune suppressive factors render the tumor-draining lymph nodes (TDLN) immune compromised, enabling tumors to invade and metastasize. Unraveling the different mechanisms underlying this immune escape will inform therapeutic intervention strategies to halt tumor spread in early clinical stages. Here, we review our findings from translational studies in melanoma, breast, and cervical cancer and discuss clinical opportunities for local immune modulation of TDLN in each of these indications.",

keywords = "Breast cancer, Cervical cancer, Local immunotherapy, Melanoma, TIMO 2018, Tumor-draining lymph node",

author = "Jossie Rotman and Koster, {Bas D.} and Jordanova, {Ekaterina S.} and Heeren, {A. Marijne} and {de Gruijl}, {Tanja D.}",

year = "2019",

month = oct,

day = "1",

doi = "10.1007/s00262-019-02330-y",

language = "English",

volume = "68",

pages = "1681--1688",

journal = "Cancer Immunology and Immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "10",

}

TY - JOUR

T1 - Unlocking the therapeutic potential of primary tumor-draining lymph nodes

AU - Rotman, Jossie

AU - Koster, Bas D.

AU - Jordanova, Ekaterina S.

AU - Heeren, A. Marijne

AU - de Gruijl, Tanja D.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Lymph nodes draining the primary tumor are essential for the initiation of an effective anti-tumor T-cell immune response. However, cancer-derived immune suppressive factors render the tumor-draining lymph nodes (TDLN) immune compromised, enabling tumors to invade and metastasize. Unraveling the different mechanisms underlying this immune escape will inform therapeutic intervention strategies to halt tumor spread in early clinical stages. Here, we review our findings from translational studies in melanoma, breast, and cervical cancer and discuss clinical opportunities for local immune modulation of TDLN in each of these indications.

AB - Lymph nodes draining the primary tumor are essential for the initiation of an effective anti-tumor T-cell immune response. However, cancer-derived immune suppressive factors render the tumor-draining lymph nodes (TDLN) immune compromised, enabling tumors to invade and metastasize. Unraveling the different mechanisms underlying this immune escape will inform therapeutic intervention strategies to halt tumor spread in early clinical stages. Here, we review our findings from translational studies in melanoma, breast, and cervical cancer and discuss clinical opportunities for local immune modulation of TDLN in each of these indications.

KW - Breast cancer

KW - Cervical cancer

KW - Local immunotherapy

KW - Melanoma

KW - TIMO 2018

KW - Tumor-draining lymph node

UR - http://www.scopus.com/inward/record.url?scp=85064506208&partnerID=8YFLogxK

U2 - 10.1007/s00262-019-02330-y

DO - 10.1007/s00262-019-02330-y

M3 - Review article

C2 - 30944963

VL - 68

SP - 1681

EP - 1688

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 10

ER -

Unlocking the therapeutic potential of primary tumor-draining lymph nodes

Abstract

Access to Document

Other files and links

Cite this